STAMFORD, CT and SYDNEY, AUSTRALIA--(MARKET WIRE)--Jun 23, 2008 -- Novogen Limited (ASX:NRT.AX - News) (NasdaqGM:NVGN - News), the registered owner of the European Patent “Use of isoflavone phyto-oestrogen extracts of soy or clover (EPO 656786 B1), has reached an Agreement with Laboratorios Casen-Fleet for a license in Spain to the Novogen Patent.
